树突分子:推进痴呆的治疗策略。

Q3 Medicine
Aditya Singh, Shubhrat Maheshwari, Vaseem Ahamad Ansari, Amita Verma, Tarique Mahmood Ansari, Juber Akhtar, Farogh Ahsan, Vishal Kumar Vishwakarma, Rufaida Wasim
{"title":"树突分子:推进痴呆的治疗策略。","authors":"Aditya Singh, Shubhrat Maheshwari, Vaseem Ahamad Ansari, Amita Verma, Tarique Mahmood Ansari, Juber Akhtar, Farogh Ahsan, Vishal Kumar Vishwakarma, Rufaida Wasim","doi":"10.2174/0118746098343913250818112618","DOIUrl":null,"url":null,"abstract":"<p><p>Dementia, characterized by a progressive decline in cognitive function, poses a significant challenge to global healthcare systems, with current therapeutic approaches offering limited efficacy. The development of nanotechnology-based drug delivery systems has introduced promising avenues for enhancing the treatment of neurodegenerative disorders such as Alzheimer's disease. Dendrimers, with their highly branched, nanoscale structure, provide an innovative platform for targeted drug delivery to the brain. Dendrimers serve as nanoscale drug carriers that facilitate controlled drug release, enhance bioavailability, and improve penetration across the blood-brain barrier (BBB), leading to superior therapeutic efficacy in neurodegenerative disorders. In particular, dendrimers can encapsulate both hydrophilic and hydrophobic drugs, increasing their stability and minimizing systemic side effects. This review explores the unique properties of dendrimers, focusing on their potential as drug delivery vehicles in dementia treatment. We also highlight advancements in the design and application of dendrimer-based therapeutics, emphasizing their role in targeting key pathological mechanisms underlying dementia. Through these approaches, dendrimers represent a promising strategy for developing more effective and personalized treatment modalities for patients suffering from cognitive impairment and dementia.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Dendrimers: Advancing Therapeutic Strategies for Dementia.\",\"authors\":\"Aditya Singh, Shubhrat Maheshwari, Vaseem Ahamad Ansari, Amita Verma, Tarique Mahmood Ansari, Juber Akhtar, Farogh Ahsan, Vishal Kumar Vishwakarma, Rufaida Wasim\",\"doi\":\"10.2174/0118746098343913250818112618\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Dementia, characterized by a progressive decline in cognitive function, poses a significant challenge to global healthcare systems, with current therapeutic approaches offering limited efficacy. The development of nanotechnology-based drug delivery systems has introduced promising avenues for enhancing the treatment of neurodegenerative disorders such as Alzheimer's disease. Dendrimers, with their highly branched, nanoscale structure, provide an innovative platform for targeted drug delivery to the brain. Dendrimers serve as nanoscale drug carriers that facilitate controlled drug release, enhance bioavailability, and improve penetration across the blood-brain barrier (BBB), leading to superior therapeutic efficacy in neurodegenerative disorders. In particular, dendrimers can encapsulate both hydrophilic and hydrophobic drugs, increasing their stability and minimizing systemic side effects. This review explores the unique properties of dendrimers, focusing on their potential as drug delivery vehicles in dementia treatment. We also highlight advancements in the design and application of dendrimer-based therapeutics, emphasizing their role in targeting key pathological mechanisms underlying dementia. Through these approaches, dendrimers represent a promising strategy for developing more effective and personalized treatment modalities for patients suffering from cognitive impairment and dementia.</p>\",\"PeriodicalId\":11008,\"journal\":{\"name\":\"Current aging science\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current aging science\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.2174/0118746098343913250818112618\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current aging science","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2174/0118746098343913250818112618","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

痴呆症以认知功能的进行性下降为特征,对全球卫生保健系统构成了重大挑战,目前的治疗方法疗效有限。基于纳米技术的药物传递系统的发展为加强神经退行性疾病如阿尔茨海默病的治疗提供了有希望的途径。树状大分子具有高度分支的纳米级结构,为靶向药物输送到大脑提供了一个创新的平台。树状大分子作为纳米级药物载体,促进药物释放控制,提高生物利用度,改善血脑屏障(BBB)的渗透,导致神经退行性疾病的卓越治疗效果。特别是,树状大分子可以封装亲水性和疏水性药物,增加其稳定性和最小化全身副作用。这篇综述探讨了树状大分子的独特性质,重点是它们在痴呆症治疗中作为药物递送载体的潜力。我们还强调了基于树突的治疗方法的设计和应用方面的进展,强调了它们在针对痴呆的关键病理机制中的作用。通过这些方法,树突分子代表了一种有希望的策略,可以为患有认知障碍和痴呆症的患者开发更有效和个性化的治疗方式。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Dendrimers: Advancing Therapeutic Strategies for Dementia.

Dementia, characterized by a progressive decline in cognitive function, poses a significant challenge to global healthcare systems, with current therapeutic approaches offering limited efficacy. The development of nanotechnology-based drug delivery systems has introduced promising avenues for enhancing the treatment of neurodegenerative disorders such as Alzheimer's disease. Dendrimers, with their highly branched, nanoscale structure, provide an innovative platform for targeted drug delivery to the brain. Dendrimers serve as nanoscale drug carriers that facilitate controlled drug release, enhance bioavailability, and improve penetration across the blood-brain barrier (BBB), leading to superior therapeutic efficacy in neurodegenerative disorders. In particular, dendrimers can encapsulate both hydrophilic and hydrophobic drugs, increasing their stability and minimizing systemic side effects. This review explores the unique properties of dendrimers, focusing on their potential as drug delivery vehicles in dementia treatment. We also highlight advancements in the design and application of dendrimer-based therapeutics, emphasizing their role in targeting key pathological mechanisms underlying dementia. Through these approaches, dendrimers represent a promising strategy for developing more effective and personalized treatment modalities for patients suffering from cognitive impairment and dementia.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current aging science
Current aging science Medicine-Geriatrics and Gerontology
CiteScore
3.90
自引率
0.00%
发文量
40
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信